Source link : https://newshealth.biz/health-news/semaglutide-shows-major-benefits-in-pad-stride/
Semaglutide, a GLP-1 agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, the drug significantly improved walking distance, symptoms like pain, and quality of life in patients with symptomatic PAD and type 2 diabetes. It was also associated with a reduction in disease progression and […]
The post Semaglutide Shows Major Benefits in PAD: STRIDE first appeared on News Health.
Author : News Health
Publish date : 2025-03-30 14:29:00
Copyright for syndicated content belongs to the linked Source.